Safety and Effectiveness of Transdermal Buprenorphine in Cancer Pain

Safety and Effectiveness of Transdermal Buprenorphine in Cancer Pain

Publication date: Mar 20, 2020

Buprenorphine transdermal patch is newly available in Taiwan in June 2017, the trade name is Transtec, and the available dosages are 35 ?g/h and 52.5 ?g/h. Taiwan is the first Asia country which launched Transtec for cancer pain treatment. Although the efficacy of transdermal buprenorphine has been demonstrated in some randomized, placebo-controlled studies and also conducted a large scale post-marketing surveillance study in Germany, therefore the local scientific data is required for Asia experience. Due to above rationale, this observational study will be initiated in Taiwan, to build up the first real-world scientific data in Asia. The objective of this study is to collect the safety and effectiveness of transdermal buprenorphine in routine clinical practice, in particular, to collect data in population with controlled cancer pain and stable titration from previous opioid analgesics in Taiwan.

Concepts Keywords
Alcohol Abuse Pain
ALT Liver metastasis
Analgesics Opioids
Asia Drugs
AST Analgesics
Buprenorphine Morphinans
Germany Ethers
Hypersensitivity Drug rehabilitation
Lactating RTT
Liver Phenols
Metastasis Buprenorphine
Nursing Transdermal patch
Opioid
Opioids
Pain
Placebo
Surveillance
Taiwan
Titration
Transdermal
Transdermal Patch
Transdermal Patches

Semantics

Type Source Name
drug DRUGBANK Buprenorphine
disease MESH Cancer
disease MESH metastasis
disease MESH liver cancer
disease MESH alcohol abuse
disease MESH hypersensitivity
disease MESH contraindications

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *